MAIA Biotechnology, Inc. (MAIA) - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the 2025 Annual Meeting of Stockholders held by MAIA Biotechnology, Inc. on May 22, 2025. The Company is an emerging growth company incorporated in Delaware with its principal executive offices in Chicago, IL. The filing details the outcomes of shareholder votes and the subsequent amendment to the Company's Certificate of Incorporation.
Key Financial Metrics
This filing is a current report regarding corporate governance and capital structure changes. It does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial performance metrics.
Material Changes and Corporate Actions
- Authorized Share Increase: Shareholders approved an amendment to increase the Company's authorized common stock from 70,000,000 shares to 150,000,000 shares. The Certificate of Amendment was filed on May 22, 2025.
- Director Elections: Stockholders re-elected both Class III director nominees, Jean-Manassé Théagène and Stan V. Smith, for three-year terms expiring in 2028.
- Auditor Ratification: Shareholders ratified the appointment of Grant Thornton LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
Voting Results and Participation
As of the record date (March 24, 2025), there were 29,587,314 shares outstanding. Approximately 66.9% of shares were present or represented by proxy at the meeting, establishing a quorum.
| Proposal | For | Against/Withheld | Abstain |
|---|---|---|---|
| Election of Jean-Manassé Théagène | 13,774,566 | 670,727 (Withheld) | N/A |
| Election of Stan V. Smith | 13,123,639 | 1,321,654 (Withheld) | N/A |
| Ratification of Auditors | 19,151,887 | 436,639 | 233,716 |
| Authorized Share Increase | 16,869,486 | 2,186,471 | 766,285 |
Guidance, Outlook, and Risks
The filing does not provide management commentary, financial guidance, or specific risk factors beyond the standard disclosure of the voting process. The increase in authorized shares provides the Company with greater flexibility for future capital raising but does not guarantee any specific issuance.
Key Facts for Investor Verification
- Verify the effective date and legal filing of the Certificate of Amendment increasing authorized shares to 150,000,000.
- Review the definitive proxy statement (filed April 8, 2025) for detailed biographies of the re-elected directors and the rationale for the share increase.
- Monitor future filings for any actual issuance of shares from the newly authorized pool.
- Confirm the Company's status as an emerging growth company and its election regarding extended transition periods for accounting standards.